A Phase 3 Study of VX-445 Combination Therapy in Cystic NCT04058353

Clinical Trial Details — Status: Completed

Administrative data
NCT number	NCT04058353
Other study ID #	VX18-445-104
Secondary ID	2018-002835-76
Status	Completed
Phase	Phase 3
First received
Last updated
Start date	August 28, 2019
Est. completion date	June 12, 2020

Study information
Verified date	June 2021
Source	Vertex Pharmaceuticals Incorporated
Contact	n/a
Is FDA regulated	No
Health authority
Study type	Interventional

Clinical Trial Summary

This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes).

Recruitment information / eligibility
Status	Completed
Enrollment	271
Est. completion date	June 12, 2020
Est. primary completion date	June 12, 2020
Accepts healthy volunteers	No
Gender	All
Age group	12 Years and older
Eligibility	Key Inclusion Criteria: - Subject has a confirmed diagnosis of CF and is heterozygous for F508del and either a gating or residual function mutation (F/G and F/RF genotypes) - Forced expiratory volume in 1 second (FEV1) value =40% and =90% of predicted mean for age, sex, and height Key Exclusion Criteria: - Clinically significant cirrhosis with or without portal hypertension - Lung infection with organisms associated with a more rapid decline in pulmonary status - Solid organ or hematological transplantation Other protocol defined Inclusion/Exclusion criteria may apply

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• ELX/TEZ/IVA
FDC tablet for oral administration.
• IVA
Mono-tablet for oral administration.
• TEZ/IVA
Fixed-dose combination (FDC) tablet for oral administration.

Locations
Country	Name	City	State
Australia	The Prince Charles Hospital	Chermside
Australia	Alfred Hospital	Melbourne, VIC
Australia	Perth Children's Hospital	Nedlands
Australia	The Royal Children's Hospital	Parkville, VIC
Australia	Mater Adult Hospital	South Brisbane
Australia	Queensland Children's Hospital	South Brisbane
Australia	Westmead Hospital	Westmead
Belgium	Cliniques Universitaires de Bruxelles Hopital Erasme	Brussels
Belgium	Universitair Ziekenhuis Brussel - Campus Jette	Brussels
Belgium	Universitair Ziekenhuis Gent	Gent
Belgium	Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg	Leuven
Canada	Stollery Children's Hospital	Edmonton
Canada	McGill University Health Center	Québec
Canada	St. Michael's Hospital	Toronto
Canada	St. Paul's Hospital	Vancouver
Denmark	Juliane Marie Center, Rigshospitalet	Copenhagen
France	Centre Hospitalier Lyon Sud	Benite Cedex
France	Groupe Hospitaler Pellegrin, CHU De Bordeaux	Bordeaux cedex
France	CHRU de Lille - Hopital Albert Calmette	Lille
France	CHU Marseille - Hopital Nord	Marseille
France	CHU de Montpellier - Hopital Arnaud de Villeneuve	Montpellier Cedex 5
France	Hopital Cochin	Paris
France	Hopital Necker, Enfants Malades	Paris Cedex 15
France	Hopital Pontchaillou CHU de Rennes	Rennes Cedex
Germany	Charite Paediatric Pulmonology Department	Berlin
Germany	Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital	Erlangen
Germany	Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen	Essen
Germany	Justus-Liebig-Universitaet Gießen Zentrum fur Kinderheilkunde und Jugendmedizin	Giessen
Germany	Universitätsklinikum Halle (Saale) / Universitätsklinik und Poliklinik für Innere Medizin, Schwerpunkt Pneumologie	Halle
Germany	Pneumologisches Studienzentrum Muenchen-West	Muenchen
Germany	University Hospital Wuerzburg	Würzburg
Ireland	Cork University Hospital	Cork
Ireland	Beaumont Hospital	Dublin
Ireland	St. Vincent's University Hospital	Dublin
Israel	University Hospital Limerick (Adults)	Limerick
Italy	Azienda Ospedaliero Universitaria Ospedale Riuniti	Ancona
Italy	IRCCS Istituto Giannina Gaslini-Ospedale Pediatrico	Genova
Italy	Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico	Milano
Italy	Malattie Apparato Respiratorio 2 - Fibrosi Cistica	Orbassano
Italy	Ospedale Pediatrico Bambino Gesu	Rome
Italy	Azienda Ospedaliera di Verona-Ospedale Civile Maggiore	Verona
Netherlands	HagaZiekenhuis van den Haag	Den Haag
Netherlands	University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis	Heidelberglaan
Netherlands	UMC St. Radboud	Nijmegen
Spain	Hospital Universitari Vall d´Hebron Servicio de Broncoscopia	Barcelona
Spain	Hospital Virgen de la Arrixaca	Murcia
Spain	Hospital Universitario Virgen del Rocio	Sevilla
Spain	Hospital Universitario y Politecnico La Fe	Valencia
United Kingdom	Papworth Hospital NHS Foundation Trust, Papworth Everard	Cambridge
United Kingdom	Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital	Exeter
United Kingdom	Clinical Research Facility, Queen Elizabeth University Hospital	Glasgow
United Kingdom	St. James University Hospital	Leeds
United Kingdom	Liverpool Heart and Chest Hospital	Liverpool
United Kingdom	Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital	London
United Kingdom	Wythenshawe Hospital	Manchester
United Kingdom	Southampton General Hospital	Southampton
United States	Michigan Medicine	Ann Arbor	Michigan
United States	Dell Children's Medical Group	Austin	Texas
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Boston Children's Hospital	Boston	Massachusetts
United States	Massachusetts General Hospital Cystic Fibrosis Center Clinical Rsearch Center	Boston	Massachusetts
United States	University of North Carolina Hospitals	Chapel Hill	North Carolina
United States	UC Health Holmes	Cincinnati	Ohio
United States	Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	The University of Texas Southwestern Medical Center	Dallas	Texas
United States	National Jewish Health	Denver	Colorado
United States	Texas Children's Hospital	Houston	Texas
United States	Indiana University	Indianapolis	Indiana
United States	The University of Iowa Hospitals and Clinics	Iowa City	Iowa
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire
United States	University of Kentucky	Lexington	Kentucky
United States	Miller Children's Hospital / Long Beach Memorial	Long Beach	California
United States	University of Wisconsin Hospital and Clinics	Madison	Wisconsin
United States	University of Miami Miller School of Medicine	Miami	Florida
United States	University of Minnesota	Minneapolis	Minnesota
United States	Northwell Health- Long Island Jewish Medical Center	New Hyde Park	New York
United States	Columbia University Medical Center	New York	New York
United States	Mount Sinai Beth Israel	New York	New York
United States	University of Oklahoma Health Sciences Center	Oklahoma City	Oklahoma
United States	Central Florida Pulmonary Group, PA	Orlando	Florida
United States	Stanford University	Palo Alto	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Children's Hospital of Pittsburgh of UPMC	Pittsburgh	Pennsylvania
United States	Oregon Health & Science University	Portland	Oregon
United States	University of California Davis Medical Center	Sacramento	California
United States	Washington University School of Medicine / St. Louis Children's Hospital	Saint Louis	Missouri
United States	University of Utah / Primary Children's Medical Center	Salt Lake City	Utah
United States	University of California San Francisco, Lung Transplant Program	San Francisco	California
United States	University of Washington Medical Center	Seattle	Washington
United States	ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center	Toledo	Ohio
United States	Banner University of Arizona Medical Center	Tucson	Arizona

Sponsors *(1)*
Lead Sponsor	Collaborator
Vertex Pharmaceuticals Incorporated

Countries where clinical trial is conducted

United States, Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Netherlands, Spain, United Kingdom,

Outcome
Type	Measure	Description	Time frame
Primary	Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for ELX/TEZ/IVA Group	FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.	From Baseline Through Week 8
Secondary	Absolute Change in Sweat Chloride (SwCl) for ELX/TEZ/IVA Group	Sweat samples were collected using an approved collection device.	From Baseline Through Week 8
Secondary	Absolute Change in ppFEV1 for the ELX/TEZ/IVA Group Compared to the Control Group	FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.	From Baseline Through Week 8
Secondary	Absolute Change in SwCl for ELX/TEZ/IVA Group Compared to the Control Group	Sweat samples were collected using an approved collection device.	From Baseline Through Week 8
Secondary	Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for ELX/TEZ/IVA Group	The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.	From Baseline Through Week 8
Secondary	Absolute Change in CFQ-R Respiratory Domain Score for ELX/TEZ/IVA Group Compared to the Control Group	The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.	From Baseline Through Week 8
Secondary	Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)		Day 1 up to Week 12

See also
Status	Clinical Trial	Phase
Completed	`NCT04696198` - Thoracic Mobility in Cystic Fibrosis Care	N/A
Completed	`NCT00803205` - Study of Ataluren (PTC124™) in Cystic Fibrosis	Phase 3
Terminated	`NCT04921332` - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD	N/A
Completed	`NCT03601637` - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del	Phase 3
Terminated	`NCT02769637` - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting	`NCT06032273` - Lung Transplant READY CF 2: CARING CF Ancillary RCT	N/A
Recruiting	`NCT06030206` - Lung Transplant READY CF 2: A Multi-site RCT	N/A
Recruiting	`NCT06012084` - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis	N/A
Recruiting	`NCT05392855` - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)	N/A
Recruiting	`NCT06088485` - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting	`NCT04056702` - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Recruiting	`NCT04039087` - Sildenafil Exercise: Role of PDE5 Inhibition	Phase 2/Phase 3
Completed	`NCT04038710` - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed	`NCT04058548` - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation	N/A
Completed	`NCT03637504` - Feasibility of a Mobile Medication Plan Application in CF Patient Care	N/A
Recruiting	`NCT03506061` - Trikafta in Cystic Fibrosis Patients	Phase 2
Completed	`NCT03566550` - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting	`NCT04828382` - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed	`NCT04568980` - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting	`NCT04010253` - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis	N/A

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Clinical Trial Details — Status: Completed

Administrative data

Study information

Clinical Trial Summary

Recruitment information / eligibility

Study Design

Related Conditions & MeSH terms

Intervention

Locations

Sponsors (1)

Countries where clinical trial is conducted

Outcome